Full-Time

Director – Medical Writing

Confirmed live in the last 24 hours

Voyager Therapeutics

Voyager Therapeutics

201-500 employees

Develops genetic medicines for neurological diseases

Biotechnology
Healthcare

Senior

Lexington, MA, USA

Category
Technical Writing
Content & Writing
Medical, Clinical & Veterinary
Requirements
  • Bachelor of Science with significant relevant writing experience OR Bachelor’s degree in English or communications with 8+ years relevant pharmaceutical experience OR Advanced degree (Masters/PhD) with 5+ years of relevant experience.
  • Experience should have been gained directly in pharmaceutical/biotechnology companies and include authoring a wide range of documents (eg, protocols, IBs, CSRs, briefing books, PIPs, special designation requests, documents contributing to global submissions, such as INDs, NDAs/BLAs, and MAAs) from inception through completion.
Responsibilities
  • Develop and implement document templates, style standards, reference library, reviewer guidelines, SOPs and quality control checklists, to ensure consistent and high-quality deliverables
  • Develop budget and resource strategies to ensure on schedule completion of medical writing deliverables, including the identification, selection, and oversight of qualified full- or part-time medical writers, vendors, consultants, or contractors
  • Lead writing strategy, drive document content and organization, develop and manage timelines, and lead comment resolution in the preparation of clear and concise clinical, nonclinical and regulatory documents supporting regulatory submissions
  • Partner with SMEs to analyze, summarize, and interpret non-clinical and clinical data
  • Collaborates with cross-functional team to review study results
  • Contributes scientific knowledge and analytical skills to the production of documents
  • Participates in developing key messages for routine documents and conducts literature searches
  • Ensures the accuracy and QC of submission-ready documents
  • Responsible for clinical trial transparency and disclosures, including clinical trials results posting on clinicaltrials.gov, EudraCT, and similar databases worldwide, in collaboration with Regulatory Affairs and Clinical Operations
  • Represents Regulatory Medical Writing as a cross-functional team member for clinical study level activities
  • Supports clinical study execution through expert review of study-level documents authored by other functions (e.g., study deviations, analysis plans, data outputs)

Voyager Therapeutics develops genetic medicines aimed at treating neurological diseases, particularly those affecting the central nervous system like amyotrophic lateral sclerosis (ALS). Their approach involves using a proprietary AAV (adeno-associated virus) capsid discovery platform, which allows for the delivery of genetic material directly to the brain through intravenous dosing. This method addresses the challenge of crossing the blood-brain barrier, which is crucial for effective treatment of brain-related conditions. Unlike many competitors, Voyager Therapeutics emphasizes collaboration with larger pharmaceutical companies to enhance their research and development efforts, which helps them accelerate the commercialization of their therapies. The company's goal is to create meaningful treatments that improve the lives of patients suffering from severe neurological conditions.

Company Stage

IPO

Total Funding

$102.1M

Headquarters

Cambridge, Massachusetts

Founded

2014

Growth & Insights
Headcount

6 month growth

3%

1 year growth

11%

2 year growth

49%
Simplify Jobs

Simplify's Take

What believers are saying

  • Voyager's recent $100 million upfront payment from Novartis highlights strong financial backing and potential for rapid growth.
  • The appointment of experienced executives like Nathan Jorgensen as CFO and Toby Ferguson as CMO strengthens the company's leadership team.
  • The selection of a development candidate for the GBA1 program in collaboration with Neurocrine Biosciences demonstrates the productivity and potential of their partnerships.

What critics are saying

  • The highly specialized focus on neurological diseases may limit market opportunities compared to broader biotech firms.
  • Dependence on partnerships and milestone payments introduces financial uncertainty if collaborations do not yield expected results.

What makes Voyager Therapeutics unique

  • Voyager Therapeutics leverages its proprietary AAV capsid discovery platform to deliver genetic material directly to the brain, a significant advancement over traditional methods.
  • The company's focus on crossing the blood-brain barrier addresses a critical challenge in treating neurological diseases, setting it apart from many competitors.
  • Voyager's strong emphasis on collaborative partnerships with major pharmaceutical companies like Novartis accelerates its R&D and commercialization efforts.

Help us improve and share your feedback! Did you find this helpful?